CRISPR Therapeutics AG Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
32.4%projected annual EPS growth
Analyst Coverage
18analysts covering
FY EPS (est.)
-$4.48next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
CASGEVY Global Patient Initiations Quarterly500.0Target: 60000 eligible patients globally
Total Cash and Marketable Securities Quarterly2.4BTarget: Maintain multi-year operational runway
Quarterly Net Loss Quarterly-122.9MTarget: Narrowing loss through commercial profit-sharing
Watch Items
- FDA Pediatric Label Expansion for CASGEVY (Ages 5-11)Trigger: FDA Priority Review DecisionAction: Assess expansion of North American and European addressable market by ~10,000 patients.
- Zugo-cel (CTX112) Phase 1/2 Clinical Trial UpdatesTrigger: Data readout in H2 2026Action: Evaluate efficacy and safety in B-cell malignancies and autoimmune indications.
- In Vivo Liver Editing Program (CTX310) ProgressTrigger: Phase 1b trial update in H2 2026Action: Review lipid reduction data and safety profile for severe hypertriglyceridemia.
Research as of 19 Jun 2026